Pyoderma

TORONTO and LAS VEGAS, Oct. 2, 2024 /PRNewswire/ -- MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria and digital wound measurement, proudly announces the presentation of 10 clinical posters featuring MolecuLight at the Symposium on Advanced Wound Care (SAWC) Fall 2024. This interdisciplinary educational event aimed at improving patient outcomes takes place from October 2–5, 2024 in Las Vegas, Nevada. It stands as one of the largest multidisciplinary meetings of wound care professionals globally. Continue Reading SAWC Fall featuring MolecuLight In addition to the clinical posters at SAWC Fall 2024, the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight Booth #431 in the Exhibition Hall. MolecuLight's showing at SAWC Fall spans a range of clinical applications and highlights new device features. These include optimized wound bed preparation ahead of skin grafting and cellular and tissue-based product (CTP) application, automatic digital wound depth measurement for streamlined workflow, thermal imaging to detect and better treat pressure injuries, associating fluorescence signals with diabetic ulcer healing, and other innovative approaches to wound care. "We are thrilled to see such a strong representation of MolecuLight research at SAWC Fall, which demonstrates the ever-growing adoption and support of our device. The 10 clinical posters being presented highlight the continuously expanding body of evidence in support of the implementation of our technology as part of the standard of care for wound infection management as this has proven to enhance patient outcomes," says Anil Amlani, CEO of MolecuLight, Inc. "MolecuLight is a unique technology in the field, with integrated multiple functions that provide clinicians with a global overview of the wounds' evolution, documents their interventions and findings and enriches every patent encounter with highly accurate, point-of-care information about bacterial burden and wound size." The clinical posters featuring the MolecuLight at SAWC Fall 2024 are as follows: Poster CR-001, "Imaging Beyond the Wound Bed: Leveraging Fluorescence Imaging of Non-Biologicals to Enhance Bacterial-Infection Management", presented by Dr. Charles Andersen Poster CR-002, "The New Age of Wound Care: Leveraging the Synergy of Multi-modal Fluorescence and Thermal Imaging", presented by Dr. Charles Andersen Poster CR-020, "Validation of a Digital Automatic-Depth Measurement Feature within a Multi-Modal Wound Imaging Device", presented by Dr. Laura Jones Poster CR-029, "Bacterial fluorescence imaging improves chronic wound biofilm detection over standard clinical assessment and blotting", presented by Dr. Laura Jones Poster CR-063, "Bacterial Fluorescence in the Application of Cellular Tissue Products", presented by Dr. Alisha Oropallo Poster CR-064, "Co-localization of High Bacterial Load with Regions of Pain in Venous Leg Ulcers: Fluorescence Imaging Informs Interventions and Validates Patient Self-Reported Pain", presented by Dr. Alisha Oropallo Poster CS-012, "Advancing Pyoderma Gangrenosum Wound Care Through Fluorescence-Guided Debridement", presented by Dr. Charles Andersen Poster CS-115, "The Interface of Cutting-Edge Technology in Mission Sustained Injuries of U.S. Special Operations", presented by Dr. Charles Andersen Poster CS-151, "The Association of Bacterial Autofluorescence Signals with Healing Outcomes in Diabetic Foot Ulcers", presented by Dr. Stephanie Woelfel Poster CS-157, "Update on pressure ulcer diagnosis and management: Leveraging Fluorescence and Thermal Imaging", presented by Dr. Charles Andersen About MolecuLight The MolecuLight i:X® and DX™ are the only Class II FDA cleared imaging devices for real-time detection of elevated levels of bacteria in wounds, surgical sites, and other injuries. With unmatched clinical evidence including 100+ peer-reviewed publications representing over 3500 patients, their innovative devices empower healthcare providers to target bacterial removal and make informed treatment decisions. By detecting bacteria in its early stages, MolecuLight technology improves infection management for exceptional patient outcomes. The multi-modal MolecuLight devices combine bacterial detection, wound measurement, and imaging capabilities into a single tool, streamlining workflows and improving documentation accuracy. Integrating seamlessly with electronic medical records, MolecuLight empowers clinicians to deliver the highest standard of care while optimizing their workflow. For more information, contact: Hunter Zudans, Director of Marketing, Moleculight Inc., T. 416.542.5507, [email protected] Photo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, September 25 – 28, 2024. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “This analysis sheds significant light on the role of C5a/C5aR signaling and vilobelimab’s ability to address the underlying inflammation driving hidradenitis suppurativa (HS), including its potential to reduce not only abscesses and nodules, but draining tunnels that remain a significant burden for many patients with this debilitating disease. In addition, we believe exploring additional efficacy parameters for HS in addition to HiSCR (Hidradenitis Suppurativa Clinical Response) could lead to a greater understanding of the disease-modifying potential of C5a inhibitors such as vilobelimab and C5aR inhibitors such as INF904, particularly with regard to reducing draining tunnels.” E-poster: P0063 Vilobelimab demonstrates significant improvement in reduction of draining tunnels, total lesion count, International Hidradenitis Suppurativa Score 4 and the newly introduced modified-HiSCR: a post hoc analysis of the Phase IIb SHINE study Authors Evangelos J. Giamarellos-Bourboulis, Christopher Sayed, Jamie Weisman, Jacek Szepietowski, Falk Bechara, Niels C. Riedemann, Camilla Chong, Hoda Tawfik SHINE was a prospective, randomized, placebo-controlled, double-blind multicenter Phase 2b trial in 177 patients with moderate to severe HS, with results announced in 2019. The post hoc analysis presented at EADV 2024 looked at other important clinical efficacy endpoints and, in particular vilobelimab 1200 mg, which was statistically significant compared to placebo at 16 weeks. Efficacy parameters assessed included the reduction of draining tunnels (dT), reduction of total lesion counts (abscesses + nodules + draining tunnels (ANdT)) and the International Hidradenitis Suppurativa Score 4 (IHS4) compared to placebo. In this post hoc analysis, vilobelimab 1200 mg demonstrated a placebo-adjusted significant reduction in dT, ANdT, and IHS4 of 45.2%, 25.1% and 31.6%, respectively. InflaRx believes this analysis suggests meaningful clinical benefit for vilobelimab in HS. Further, it supports utilizing a modified version of the HiSCR that measures drug activity against all three lesion types with an emphasis on the reduction of dT, a critical manifestation of the disease that greatly impacts patients’ quality of life. About GOHIBIC (vilobelimab) Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism of the innate immune system, which is not the case for molecules blocking C5. In pre-clinical studies, vilobelimab has been shown to control the inflammatory response-driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response. In addition to development in COVID-19, vilobelimab is also being developed for various debilitating or life-threatening inflammatory indications, including pyoderma gangrenosum (PG). In April 2023, the FDA issued the EUA for GOHIBIC (vilobelimab) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). In January 2024, InflaRx announced the launch of The InflaRx Commitment Program, pursuant to which the cost of GOHIBIC (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements, for patients who were administered GOHIBIC (vilobelimab) in line with its EUA and who died due to COVID-19 in the intensive care unit. The Marketing Authorization Application (MAA) for the treatment of adult patients with SARS-CoV-2 induced septic ARDS receiving IMV or ECMO is under regulatory review by the European Committee for Medicinal Products for Human Use under the centralized procedure, which applies to all 27 member states of the European Union. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx). Contacts: InflaRx N.V.MC Services AGJan Medina, CFAVice President, Head of Investor RelationsEmail: IR@inflarx.deKatja Arnold, Laurie Doyle, Dr. Regina LutzEmail: inflarx@mc-services.eu Europe: +49 89-210 2280U.S.: +1-339-832-0752 FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

10 povidone iodine solution in this article refers to 10% povidone iodine solution, which means that this solution contains 10% povidone iodine (equivalent to 1% titratable iodine) and is a disinfectant. What are the main uses of 10 povidone iodine solution?   About povidone iodine Povidone iodine is a loose complex formed by combining elemental iodine and a polymer carrier, with povidone acting as a carrier and solubilizer. It is a yellow-brown to brown-red amorphous powder at room temperature. It has a slight odor and is easily soluble in water or ethanol. The aqueous solution is acidic and insoluble in ether, chloroform, acetone, ethane and carbon tetrachloride. Povidone iodine solution does not have the disadvantages of iodine tincture, is lightly colored, easy to wash off, has little irritation to the mucous membrane, does not require ethanol deiodination, has no corrosive effect, and has low toxicity.   10 povidone iodine solution can effectively kill Newcastle disease, bursal disease, avian influenza, mycoplasma, Escherichia coli, salmonella, influenza, blue ear disease, etc. It can also kill parasite eggs of livestock and poultry, and inhibit the breeding of insects such as mosquitoes and flies. It can also be used in fruit trees, crops, fish and shrimp farming.   10 povidone iodine solution is an external disinfectant used for cuts, abrasions, burns and minor skin wounds. Its mechanism of action is that after this product contacts the wound or the affected area, it can depolymerize and release the iodine contained to exert a bactericidal effect. It has the characteristics of low irritation to tissues and is suitable for skin and mucous membrane infections. It is usually used for purulent dermatitis, fungal skin infection, and small-area mild burns and scalds. It is also used to disinfect small-area skin and mucosal wounds. It is also a medical disinfectant used for skin preparation before surgery, or a disinfectant and cleanser for skin preparation before injection.   10 povidone iodine solution is a solution mainly used for skin wound disinfection. It does not need to be diluted when used. The disinfectant is applied directly to the damaged skin. It should be applied within 3-5cm around the lesion and applied twice a day. If necessary, the wound can be covered with sterile gauze to avoid infection.   In summary, 10 povidone iodine solution is the most common topical disinfectant. When you need to treat the wound yourself after an injury to the outside of the body, 10 povidone iodine solution is a good choice.